BEAM vs REGN · rev $63.5M vs P/E 14, rev $14.34B
Beam Therapeutics Inc (BEAM) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported BEAM revenue for 2024-12-31 was $63.5M. Net income was -$376.7M. Revenue was down 83.2% from 2023-12-31 to 2024-12-31. BEAM currently screens at market cap $2.01B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
BEAM currently screens at market cap $2.01B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the BEAM and REGN stock pages for the full models.
Not investment advice.